Skip to Main Content

Advertisement

Umbrella Alt Text
header search
Search
Advanced Search
Skip Nav Destination

Predictors of the Response to Gefitinib in Refractory Non–Small Cell Lung Cancer

Clin Cancer Res (2005) 11 (6): 2244–2251.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
Molecular modelling of antiproliferative inhibitors based on SMILES descriptors using Monte-Carlo method, docking, MD simulations and ADME/Tox studies
  • Kamal Tabti
  • Larbi Elmchichi
  • Abdelouahid Sbai
  • Hamid Maghat
  • Mohammed Bouachrine
  • Tahar Lakhlifi
Molecular Simulation (2022) 48 (17): 1575.
Comparing the Therapeutic Efficacies of Lung Cancer: Network Meta-Analysis Approaches
  • Chuan-Hsin Chang
  • Yue-Cune Chang
International Journal of Environmental Research and Public Health (2022) 19 (21): 14324.
Phosphorylation of serine/arginine‐rich splicing factor 1 at tyrosine 19 promotes cell proliferation in pediatric acute lymphoblastic leukemia
  • Liting Xu
  • Han Zhang
  • Mei Mei
  • Chaohao Du
  • Xiahe Huang
  • Jing Li
  • Yingchun Wang
  • Shilai Bao
  • Huyong Zheng
Cancer Science (2018) 109 (12): 3805.
Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors
  • F. Koinis
  • A. Voutsina
  • A. Kalikaki
  • A. Koutsopoulos
  • E. Lagoudaki
  • E. Tsakalaki
  • E. K. Dermitzaki
  • E. Kontopodis
  • A. G. Pallis
  • V. Georgoulias
  • A. Kotsakis
Clinical and Translational Oncology (2018) 20 (2): 140.
Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports
  • Yongmei Liu
  • Yan Zhang
  • Li Zhang
  • Bin Liu
  • Yongsheng Wang
  • Xiaojuan Zhou
  • Yanying Li
  • Qian Zhao
  • Youling Gong
  • Lin Zhou
  • Jiang Zhu
  • Zhenyu Ding
  • Jin Wang
  • Feng Peng
  • Meijuan Huang
  • Lu Li
  • Li Ren
  • You Lu
Oncotarget (2017) 8 (30): 49680.
Theoretical method for evaluation of therapeutic effects and adverse effects of epidermal growth factor receptor tyrosine kinase inhibitors in clinical treatment
  • Koji Kimura
  • Risa Takayanagi
  • Tomoki Fukushima
  • Yasuhiko Yamada
Medical Oncology (2017) 34 (10)
Efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation: a pooled analysis
  • Jingqi Zhuang
  • Yongfeng Yu
  • Ziming Li
  • Shun Lu
Oncotarget (2017) 8 (32): 53675.
A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma
  • Chuanhua Zhao
  • Li Lin
  • Jianzhi Liu
  • Rongrui Liu
  • Yuling Chen
  • Feijiao Ge
  • Ru Jia
  • Yang Jin
  • Yan Wang
  • Jianming Xu
Oncotarget (2016) 7 (35): 57310.
Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma
  • Hayoung Choi
  • Jinsun Chang
  • Hong-Joon Shin
  • Cheol-Kyu Park
  • In-Jae Oh
  • Kyu-Sik Kim
  • Young-Chul Kim
Thoracic Cancer (2015) 6 (2): 224.
Receptor tyrosine kinase structure and function in health and disease
  • Oleg A. Karpov
  • Gareth W. Fearnley
  • Gina A. Smith
  • Jayakanth Kankanala
  • Michael J. McPherson
  • Darren C. Tomlinson
  • Michael A. Harrison
  • Sreenivasan Ponnambalam
AIMS Biophysics (2015) 2 (4): 476.
Clinical significance of gefitinib antitumor activity in patients with lung adenocarcinoma
  • ZHUN WANG
  • QIAN-BO HAN
  • JIA-LEI GU
  • XIN-MIN YU
  • XIAO-JIANG SUN
  • QING-REN LIN
  • JUN FANG
  • YUE-ZHEN WANG
  • YA-PING XU
  • WEI-MIN MAO
Oncology Letters (2015) 9 (1): 257.
Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC
  • Luis Paz-Ares
  • Denis Soulières
  • Joachim Moecks
  • Ilze Bara
  • Tony Mok
  • Barbara Klughammer
Journal of Cellular and Molecular Medicine (2014) 18 (8): 1519.
Novel agents in development for advanced non-small cell lung cancer
  • Thomas E. Stinchcombe
Therapeutic Advances in Medical Oncology (2014) 6 (5): 240.
Positron emission tomography-computed tomography on predicting the efficacy of targeted therapy for lung adenocarcinoma
  • Xiaoxiang Rong
  • Xiaoli Cai
  • Rong Li
  • Jinzhang Chen
  • Quanshi Wang
  • Changxuan You
  • Wenyun Wu
  • Chuanxin Liu
  • Junyi Zhang
  • Rongcheng Luo
Thoracic Cancer (2014) 5 (4): 297.
Comprehensive Analysis of Oncogenic Mutations in Lung Squamous Cell Carcinoma With Minor Glandular Component
  • Yunjian Pan
  • Rui Wang
  • Ting Ye
  • Chenguang Li
  • Haichuan Hu
  • Yongfu Yu
  • Yang Zhang
  • Lei Wang
  • Xiaoyang Luo
  • Hang Li
  • Yuan Li
  • Lei Shen
  • Yihua Sun
  • Haiquan Chen
Chest (2014) 145 (3): 473.
Targeted Therapies for Locally Advanced or Metastatic Squamous Cell Carcinoma of the Lung
  • Thomas E. Stinchcombe
Current Treatment Options in Oncology (2013) 14 (4): 568.
EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer
  • Hsiang-Fong Kao
  • Chia-Chi Lin
  • James Chih-Hsin Yang
Future Oncology (2013) 9 (7): 991.
Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets
  • Justin M. Drake
  • Nicholas A. Graham
  • John K. Lee
  • Tanya Stoyanova
  • Claire M. Faltermeier
  • Sudha Sud
  • Björn Titz
  • Jiaoti Huang
  • Kenneth J. Pienta
  • Thomas G. Graeber
  • Owen N. Witte
Proceedings of the National Academy of Sciences (2013) 110 (49)
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
  • Neal I. Lindeman
  • Philip T. Cagle
  • Mary Beth Beasley
  • Dhananjay Arun Chitale
  • Sanja Dacic
  • Giuseppe Giaccone
  • Robert Brian Jenkins
  • David J. Kwiatkowski
  • Juan-Sebastian Saldivar
  • Jeremy Squire
  • Erik Thunnissen
  • Marc Ladanyi
Archives of Pathology & Laboratory Medicine (2013) 137 (6): 828.
Repeated Favorable Responses to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in a Case of Advanced Lung Adenocarcinoma
  • Eun-Young Kim
  • Yoon-Hee Kim
  • Hee-Jung Ban
  • In-Jae Oh
  • Yong-Soo Kwon
  • Kyu-Sik Kim
  • Yu-Il Kim
  • Sung-Chul Lim
  • Young-Chul Kim
Tuberculosis and Respiratory Diseases (2013) 74 (3): 129.
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors
  • Neal I. Lindeman
  • Philip T. Cagle
  • Mary Beth Beasley
  • Dhananjay Arun Chitale
  • Sanja Dacic
  • Giuseppe Giaccone
  • Robert Brian Jenkins
  • David J. Kwiatkowski
  • Juan-Sebastian Saldivar
  • Jeremy Squire
  • Erik Thunnissen
  • Marc Ladanyi
The Journal of Molecular Diagnostics (2013) 15 (4): 415.
Ascertaining an Appropriate Diagnostic Algorithm Using EGFR Mutation-Specific Antibodies to Detect EGFR Status in Non-Small-Cell Lung Cancer
  • Guiyang Jiang
  • Chuifeng Fan
  • Xiupeng Zhang
  • Qianze Dong
  • Liang Wang
  • Yang Liu
  • Shundong Dai
  • Lianhe Yang
  • Yong Zhang
  • Juanhan Yu
  • Enhua Wang
  • Hiromu Suzuki
PLoS ONE (2013) 8 (3): e59183.
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
  • Neal I. Lindeman
  • Philip T. Cagle
  • Mary Beth Beasley
  • Dhananjay Arun Chitale
  • Sanja Dacic
  • Giuseppe Giaccone
  • Robert Brian Jenkins
  • David J. Kwiatkowski
  • Juan-Sebastian Saldivar
  • Jeremy Squire
  • Erik Thunnissen
  • Marc Ladanyi
Journal of Thoracic Oncology (2013) 8 (7): 823.
Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations
  • Natasha Rekhtman
  • Paul K. Paik
  • Maria E. Arcila
  • Laura J. Tafe
  • Geoffrey R. Oxnard
  • Andre L. Moreira
  • William D. Travis
  • Maureen F. Zakowski
  • Mark G. Kris
  • Marc Ladanyi
Clinical Cancer Research (2012) 18 (4): 1167.
Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression
  • Justin M. Drake
  • Nicholas A. Graham
  • Tanya Stoyanova
  • Amir Sedghi
  • Andrew S. Goldstein
  • Houjian Cai
  • Daniel A. Smith
  • Hong Zhang
  • Evangelia Komisopoulou
  • Jiaoti Huang
  • Thomas G. Graeber
  • Owen N. Witte
Proceedings of the National Academy of Sciences (2012) 109 (5): 1643.
Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: A single-arm, open-label, phase II study
  • In-Jae Oh
  • Hee-Jung Ban
  • Kyu-Sik Kim
  • Young-Chul Kim
Lung Cancer (2012) 77 (1): 121.
Clinicopathological features of lung adenocarcinoma with KRAS mutations
  • Seiichi Kakegawa
  • Kimihiro Shimizu
  • Masayuki Sugano
  • Yohei Miyamae
  • Kyoichi Kaira
  • Takuya Araki
  • Tetsuhiro Nakano
  • Mitsuhiro Kamiyoshihara
  • Osamu Kawashima
  • Izumi Takeyoshi
Cancer (2011) 117 (18): 4257.
Part 4: Pharmacogenetic Variability in Anticancer Pharmacodynamic Drug Effects
  • Maarten J. Deenen
  • Annemieke Cats
  • Jos H. Beijnen
  • Jan H.M. Schellens
The Oncologist (2011) 16 (7): 1006.
EGFR Mutations and Lung Cancer
  • Gilda da Cunha Santos
  • Frances A. Shepherd
  • Ming Sound Tsao
Annual Review of Pathology: Mechanisms of Disease (2011) 6 (1): 49.
Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: A pooled analysis of published reports
  • Takehito Shukuya
  • Toshiaki Takahashi
  • Rieko Kaira
  • Akira Ono
  • Yukiko Nakamura
  • Asuka Tsuya
  • Hirotsugu Kenmotsu
  • Tateaki Naito
  • Kyoichi Kaira
  • Haruyasu Murakami
  • Masahiro Endo
  • Kazuhisa Takahashi
  • Nobuyuki Yamamoto
Cancer Science (2011) 102 (5): 1032.
Targeted Therapies for Lung Cancer
  • Jill E. Larsen
  • Tina Cascone
  • David E. Gerber
  • John V. Heymach
  • John D. Minna
The Cancer Journal (2011) 17 (6): 512.
Clinicopathologic Factors Affecting the Progression-Free Survival of Patients With Advanced Non–Small-Cell Lung Cancer After Gefitinib Therapy
  • Katsuhiro Masago
  • Shiro Fujita
  • Yosuke Togashi
  • Young Hak Kim
  • Yukimasa Hatachi
  • Akiko Fukuhara
  • Hiroki Nagai
  • Yuichi Sakamori
  • Tadashi Mio
  • Michiaki Mishima
Clinical Lung Cancer (2011) 12 (1): 56.
Is FISH floating or still swimming in the lung cancer ocean?
  • F. Cappuzzo
  • D.R. Camidge
  • M. Varella-Garcia
Annals of Oncology (2011) 22 (3): 493.
The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma
  • Yoshiki Kozu
  • Koji Tsuta
  • Takashi Kohno
  • Ikuo Sekine
  • Akihiko Yoshida
  • Shunichi Watanabe
  • Tomohide Tamura
  • Jun Yokota
  • Kenji Suzuki
  • Hisao Asamura
  • Koh Furuta
  • Hitoshi Tsuda
Lung Cancer (2011) 73 (1): 45.
Introducing, OncoTarget
  • Mikhail Blagosklonny
  • Andrei Gudkov
Oncotarget (2010) 1 (1): 2.
Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib
  • Fengsheng Chen
  • Xi Luo
  • Jinbiao Zhang
  • Yang Lu
  • Rongcheng Luo
Medical Oncology (2010) 27 (3): 950.
Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status
  • Aristea Kalikaki
  • Anastasios Koutsopoulos
  • Dora Hatzidaki
  • Maria Trypaki
  • Emmanouel Kontopodis
  • Efstathios Stathopoulos
  • Dimitris Mavroudis
  • Vassilis Georgoulias
  • Alexandra Voutsina
Lung Cancer (2010) 69 (1): 110.
Study of the correlation of EGFR and K-RAS gene mutations with its protein expression in non-small cell lung cancer
  • Huan-ling Luan
  • Lei-na Sun
  • Na Dong
  • Yan Guo
  • Bao-cun Sun
  • Zhong-li Zhan
Clinical Oncology and Cancer Research (2010) 7 (2): 97.
Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer
  • Victor Cohen
  • Jason S. Agulnik
  • Celina Ang
  • Goulnar Kasymjanova
  • Gerald Batist
  • David Small
  • Guilherme Brandao
  • George Chong
  • Wilson H. Miller
Cancer (2010) 116 (18): 4309.
Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations
  • Kimihide Yoshida
  • Yasushi Yatabe
  • Jangchul Park
  • Shizu Ogawa
  • Ji Young Park
  • Junichi Shimizu
  • Yoshitsugu Horio
  • Keitaro Matsuo
  • Tetsuya Mitsudomi
  • Toyoaki Hida
Journal of Cancer Research and Clinical Oncology (2010) 136 (4): 527.
Molecular Diagnostics Testing for Lung Adenocarcinoma
  • Lynette M. Sholl
  • Neal I. Lindeman
Pathology Case Reviews (2010) 15 (4): 103.
Good Clinical Response to Gefitinib in a Non-small Cell Lung Cancer Patient Harboring a Rare Somatic Epidermal Growth Factor Gene Point Mutation; Codon 768 AGC > ATC in Exon 20 (S768I)
  • K. Masago
  • S. Fujita
  • K. Irisa
  • Y. H. Kim
  • M. Ichikawa
  • T. Mio
  • M. Mishima
Japanese Journal of Clinical Oncology (2010) 40 (11): 1105.
Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis
  • Luis Paz-Ares
  • Denis Soulières
  • Ivan Melezínek
  • Joachim Moecks
  • Lorenz Keil
  • Tony Mok
  • Rafael Rosell
  • Barbara Klughammer
Journal of Cellular and Molecular Medicine (2010) 14 (1-2): 51.
Micrometastasis, molecular markers, and their future role with EUS-guided FNA
  • Michael B. Wallace
Gastrointestinal Endoscopy (2009) 69 (2): S152.
Lung Cancer in Never Smokers: Molecular Profiles and Therapeutic Implications
  • Charles M. Rudin
  • Erika Avila-Tang
  • Curtis C. Harris
  • James G. Herman
  • Fred R. Hirsch
  • William Pao
  • Ann G. Schwartz
  • Kirsi H. Vahakangas
  • Jonathan M. Samet
Clinical Cancer Research (2009) 15 (18): 5646.
Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma
  • Sung Hoon Sim
  • Sae-Won Han
  • Do-Youn Oh
  • Se-Hoon Lee
  • Dong-Wan Kim
  • Seock-Ah Im
  • Doo Hyun Chung
  • Tae-You Kim
  • Jong Seok Lee
  • Young Whan Kim
  • Dae Seog Heo
  • Yung-Jue Bang
Lung Cancer (2009) 65 (2): 204.
Immunohistochemical analysis of phosphorylated epidermal growth factor receptor might provide a surrogate marker of EGFR mutation
  • Hideki Endoh
  • Yasunori Ishibashi
  • Ei Yamaki
  • Takeshi Yoshida
  • Toshiki Yajima
  • Hitoshi Kimura
  • Takayuki Kosaka
  • Ryoichi Onozato
  • Shigebumi Tanaka
  • Tetsuya Mitsudomi
  • Hiroyuki Kuwano
Lung Cancer (2009) 63 (2): 241.
Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors
  • T John
  • G Liu
  • M-S Tsao
Oncogene (2009) 28 (S1): S14.
Beyond Doublet Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Combination of Targeted Agents with First-Line Chemotherapy
  • Roy S. Herbst
  • Thomas J. Lynch
  • Alan B. Sandler
Clinical Lung Cancer (2009) 10 (1): 20.
Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis
  • Josh John Carlson
  • Louis P. Garrison
  • Scott D. Ramsey
  • David L. Veenstra
Journal of Cancer Research and Clinical Oncology (2009) 135 (11): 1483.
  • Online ISSN 1557-3265
  • Print ISSN 1078-0432

AACR Journals

 

 

  • Copyright © 2022 by the American Association for Cancer Research.
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept